Children suffering from fever and cold
"fever" AND "upper respiratory infection" AND "children"
Note on moderate fever: Moderate fever is not always harmful - it is associated with decreased microbial reproduction and an enhanced immune response. Temperatures below 39°C in a healthy, comfortable child generally do not require drug treatment.
| Drug | Dose | Notes |
|---|---|---|
| Paracetamol (Acetaminophen) | 15 mg/kg/dose PO or PR every 4-6 hours (max 80 mg/kg/day, up to 5 doses/day) | First-line; safe from birth |
| Ibuprofen | 10 mg/kg/dose every 6-8 hours (max 40 mg/kg/day) | Use only in children >6 months of age |
| Supportive Measure | Details |
|---|---|
| Saline nasal drops | Safe and effective for loosening secretions |
| Bulb syringe suctioning | Especially helpful before feeds and sleep |
| Cool-mist humidifier | Safer than warm-steam humidifiers (avoids burn risk) |
| Warm steam (e.g., shower steam) | Effective for nasal congestion relief |
| Honey (children >1 year) | Can soothe a sore throat |
| Adequate fluids and rest | Prevents dehydration, supports recovery |
Caution: Bulb suctioning done too frequently can cause nasal trauma, mucosal swelling, and worsening congestion.
| Drug/Drug Class | Reason to Avoid |
|---|---|
| OTC cough and cold preparations (decongestants, antihistamines) | No proven benefit; significant side effects and toxicity risk in young children |
| Antihistamines | Cold-related rhinorrhea is NOT histamine-mediated; antihistamines do not help and can cause tachycardia, agitation, hyperactivity, and seizures in toxic doses |
| Intranasal/oral decongestants | Not proven effective in young children; can cause significant side effects |
| Codeine/opioids | Not recommended for cough in children |
| Aspirin | Risk of Reye syndrome |
For older children and adolescents, adult-style symptomatic treatment (acetaminophen/NSAIDs for fever, ibuprofen for sore throat, oxymetazoline nasal spray for congestion, dextromethorphan for cough) may be considered.
| Age Group | Key Points |
|---|---|
| Neonates (<1 month) | Any fever is an emergency - admit for full sepsis workup (CBC, blood/urine cultures, LP); relative immunodeficiency |
| Infants 1-3 months | High risk for serious bacterial illness; full workup often needed |
| 3-36 months | Source of infection may be unclear; fever >39°C warrants investigation |
| >36 months | Children are easier to evaluate; complaints are usually more localizing; group A Streptococcal pharyngitis becomes more common in school-age children |
| Situation | Action |
|---|---|
| Mild fever (<39°C), child comfortable | Supportive care, reassurance, fluids |
| Fever ≥39°C or child uncomfortable | Acetaminophen 15 mg/kg; Ibuprofen 10 mg/kg if >6 months |
| Nasal congestion (any age) | Saline drops + bulb suction + humidifier |
| Cough/runny nose in <6 yr | NO OTC cough/cold drugs; supportive care only |
| Aspirin for cold/fever | NEVER give to children |
| Antibiotic | Only if bacterial infection confirmed |
| Any fever in neonate <1 month | Emergency - go to hospital immediately |
6 year child hypothermia emergency medicine
"hypothermia" AND "children" AND "emergency"
PMID: 41122889
hypothermia ECG J wave Osborn wave

A standard 12-lead electrocardiogram (ECG) demonstrating characteristic findings of hypothermia (recorded at a core body temperature of 28.1°C). The most prominent finding is the presence of Osborn waves (J waves), visualized as a positive deflection or hump at the junction between the QRS complex and the ST segment. These are most marked in the inferior leads (II, III, aVF) and lateral precordial leads (V4-V6), indicated by red arrows. The image shows a dynamic variation in J-wave amplitude, particularly following premature atrial contractions (PACs), where the morphology and height of the deflection change in response to varying RR intervals (labeled as 1115ms, 548ms, and 462ms). Additional features include giant R waves in leads with prominent J waves, a vertical P-wave axis, and a rightward QRS axis shift. The baseline shows minor tremors, common in hypothermic patients. This visual is an educational example of J-point elevation morphology in systemic hypothermia and its relationship with cardiac cycle length.

A standard 12-lead electrocardiogram (ECG) displayed on a grid with a paper speed of 25 mm/s and voltage of 10 mm/mV. The tracing demonstrates sinus tachycardia with a heart rate of approximately 105 beats per minute. P waves are present and consistently associated with a narrow QRS complex, suggesting a normal cardiac conduction pathway. The R-R intervals are regular throughout the recording, indicating a stable rhythm without arrhythmias or ectopic beats. Notable morphological features include non-specific T-wave changes in the lateral leads (I, aVL, V5, V6), which are characterized by slight flattening or subtle variations in shape. The precordial leads show normal R-wave progression from V1 to V5. This diagnostic image represents a follow-up ECG following rewarming in a patient with previous hypothermia-related changes, showing the resolution of Osborn (J) waves and first-degree atrioventricular block, returning to a baseline clinical state.
Harrison's Principles of Internal Medicine 22E documents the lowest recorded core temperature with successful resuscitation in a child: 11.8°C in a 2-year-old - demonstrating that profound hypothermia can be survived with aggressive management.
| Severity | Core Temperature | CNS | Cardiovascular | Respiratory | Neuromuscular |
|---|---|---|---|---|---|
| Mild | 35°C - 32.2°C (95°F - 90°F) | Amnesia, impaired judgment, dysarthria, apathy | Tachycardia then progressive bradycardia; vasoconstriction | Tachypnea then declining respiratory volume | Shivering (effective) |
| Moderate | <32.2°C - 28°C (90°F - 82.4°F) | EEG abnormalities, progressive LOC, pupil dilation, hallucinations, paradoxical undressing | Pulse and CO falling; atrial/ventricular arrhythmias; J (Osborn) waves on ECG | Hypoventilation; loss of airway reflexes | Hyporeflexia; shivering fails; rigidity |
| Severe | <28°C (<82.4°F) | Coma, loss of ocular reflexes, declining EEG | Severely reduced BP/HR/CO; VF risk maximal; asystole | Apnea; pulmonary edema | No movement; areflexia; no corneal reflexes |


| Method | Details |
|---|---|
| Forced-air warming blanket | Most practical and efficient; no afterdrop; safe in ED |
| Warm water circulating pads | Thermostatic systems around trunk |
| Radiant heat source | Useful for infants/young children |
| Hot water bottles | Apply to trunk/axillae/groin only - NOT extremities |
Critical warning: Do NOT apply heat to extremities in chronic/severe hypothermia - this causes peripheral vasodilation, sends cold blood to the core, and causes core temperature afterdrop (continued drop in core temperature after removal from cold). Apply heat to the truncal region only.
| Technique | Details |
|---|---|
| Heated humidified oxygen (40-45°C) | Via mask or ETT; simple, widely available; adds 1-2°C/hr; eliminates respiratory heat loss |
| Warmed IV crystalloids (40-42°C) | Significant heat gain during volume resuscitation |
| Warmed bladder/gastric irrigation | Minimal heat transfer alone; adjunct only |
| ECMO (extracorporeal rewarming) | For cardiac arrest with refractory VF; most effective technique |
Rosen's Emergency Medicine states: "Aggressive treatment of hypothermia is indicated in infants [and children]. Rapid rewarming is advantageous because it minimizes energy expenditure." A neonate with core temp 14.8°C and in CPR made a full neurologic recovery after active external rewarming + warmed IV fluids + heated humidified ventilator gases.
| Core Temp | Defibrillation | Action |
|---|---|---|
| >28°C | Attempt up to 3 shocks at max power | Standard ACLS/PALS |
| <28°C | Defibrillation usually fails | Rewarm to ≥30°C first, then retry |
| Any | CPR | Continue CPR throughout rewarming; do NOT stop |
| Pitfall | Explanation |
|---|---|
| Coagulation tests are falsely normal | Tests run at 37°C; in vivo coagulopathy is present. Treatment is rewarming, NOT plasma/platelets. |
| Hematocrit falsely elevated | Rises 2% for every 1°C drop - anemia may be masked |
| WBC falsely low | White cell sequestration and bone marrow suppression mask infection |
| Electrolytes unpredictable | Hyperkalemia enhanced cardiac toxicity; ECG changes obscured |
| Blood gases: do NOT correct for temperature | An uncorrected pH 7.42 and PCO2 40 mmHg = appropriate at any core temp; over-ventilating causes dangerous alkalosis |
| Hypoglycemia | Common and must be treated immediately; check bedside glucose in every hypothermic child |
| Drug effects are temperature-dependent | Medications work unpredictably when cold; overdosing for "no effect" causes toxicity on rewarming |
HYPOTHERMIA IN A 6-YEAR-OLD
│
▼
1. Remove cold/wet clothing. Dry. Cover (including head).
→ IV access, glucose check, cardiac monitor, core temp
│
▼
2. Is there a pulse? (Check 60 seconds or use ECHO)
├── YES → Go to rewarming
└── NO → Start CPR immediately. Do NOT stop.
│
▼
3. Rewarming (children = age extreme = ACTIVE required)
Mild (>32°C, stable): Passive + heated humidified O2
Moderate (<32°C): AER (forced air blanket, trunk) + heated O2 + warm IV fluids
Severe (<28°C, VF): Active core rewarming + ECMO if available
│
▼
4. Defibrillate only if core temp >28°C
(or after rewarming to ≥30°C)
│
▼
5. Treat precipitating cause
Glucose, antibiotics (if sepsis), toxicology screen
Can we give Hydrocortisone in this situation?
"Although failure to rewarm spontaneously has been noted in victims with hypothyroidism and other endocrine deficiencies, reserve the use of thyroid hormones and corticosteroids for patients with suspected thyroid and adrenal insufficiency, respectively."
| Drug | Dose | Route | Timing |
|---|---|---|---|
| Hydrocortisone | 100-200 mg | IV | Give first, before starting thyroid hormone |
| Followed by maintenance | 25 mg IV every 6 hours | IV | Until adrenal insufficiency is excluded |
"For myxedema crisis, give a stress dose of hydrocortisone (100 to 200 milligrams IV) at the start of therapy. Obtain serum cortisol levels prior to initiation of therapy, but it is not necessary to wait for results."
"Hydrocortisone (50 mg every 6 hours until adrenal insufficiency is excluded) are usually added prior to starting L-thyroxine because of the concern of associated adrenal insufficiency."
| Reason | Explanation |
|---|---|
| No benefit in pure accidental hypothermia | Hypothermia from cold exposure alone does not involve adrenal failure; rewarming corrects everything |
| Drug effects are temperature-dependent | At low core temperatures, drugs work unpredictably; dosing for "no effect" when cold causes toxicity on rewarming - a key danger emphasized by Rosen's EM |
| Immunosuppression risk | Corticosteroids impair neutrophil function (already impaired by cold); increases infection risk |
| Hyperglycemia risk | Can worsen metabolic derangements |
| Masks diagnostic features | May obscure signs of underlying infection or inflammation |
Is the child failing to rewarm despite good technique?
│
├── NO → Continue standard rewarming. No steroids.
│
└── YES → Consider secondary hypothermia
│
├── Evidence of hypothyroidism?
│ (bradycardia, puffy face, dry skin,
│ delayed relaxation of reflexes, low T4/TSH)
│ └── YES → Myxedema crisis
│ Give Hydrocortisone 100-200 mg IV FIRST
│ Then add thyroid hormone replacement
│
├── Evidence of adrenal crisis?
│ (refractory hypotension, hyponatremia,
│ hyperkalemia, hypoglycemia, skin pigmentation)
│ └── YES → Give Hydrocortisone 50-100 mg IV
│ (stress dosing)
│
└── Neither suspected → Standard rewarming +
treat other causes
(sepsis, toxins, CNS injury)
| Scenario | Hydrocortisone? | Dose |
|---|---|---|
| Simple accidental hypothermia (cold exposure) | ❌ No | Not indicated |
| Hypothermia + failure to rewarm + suspected AI | ✅ Yes | 50-100 mg IV |
| Myxedema crisis with hypothermia | ✅ Yes (before thyroid hormone) | 100-200 mg IV |
| Septic shock + hypothermia (refractory) | Consider (stress dose) | 1-2 mg/kg IV |
Bottom line: Hydrocortisone treats the endocrine cause of hypothermia, not the hypothermia itself. The treatment of hypothermia is rewarming.
I have seen doctor prescribing hydrocortisone inj in hyperthermia, bradycardia and low spo2 after surgeries like tkr and thr
| Condition | Hyperthermia | Bradycardia | Low SpO2 | Timing |
|---|---|---|---|---|
| Fat Embolism Syndrome (FES) | Yes (fever) | Reflex/compensatory | Yes (key feature) | 12-72 hrs post-op |
| Bone Cement Implantation Syndrome (BCIS) | Possible | Yes (cardiac depression) | Yes (V/Q mismatch) | Intraoperative/immediate |
| Pulmonary Embolism (PE) | Yes (low-grade) | Reflex bradycardia in massive PE | Yes | Hours to days post-op |
| SIRS / Post-op Systemic Inflammatory Response | Yes | Can occur | Yes | 24-48 hrs post-op |
| Anaphylaxis (cement, antibiotics, latex) | Yes | Possible | Yes (bronchospasm) | Intraoperative/immediate |
"There is currently no evidence supporting the use of steroids, heparin, or dextran in the management of FES."
"The use of corticosteroid therapy in preventing or treating fat embolism syndrome is controversial."
| Drug | Role | Dose (Adult) |
|---|---|---|
| Epinephrine (Adrenaline) | First-line - MUST give first | 0.3-0.5 mg IM |
| Hydrocortisone | Second-line - prevents biphasic reaction | 200 mg IV |
| Chlorphenamine | Second-line antihistamine | 10 mg IV |
| IV fluids | For hypotension | Rapid bolus |
Important: In anaphylaxis, hydrocortisone does NOT act fast enough to treat the acute attack - it takes 4-6 hours to work. Its role is to prevent a biphasic (second-wave) reaction 4-12 hours later. Epinephrine always comes first.
| Indication | Evidence Level | Mechanism | Dose |
|---|---|---|---|
| FES - anti-inflammatory | Controversial; no RCT proof but widely used | Reduces inflammatory cascade, capillary leak | 100-200 mg IV |
| BCIS - anti-inflammatory | Empirical; part of supportive care | Blunts cytokine/COX storm | 100-200 mg IV |
| Anaphylaxis | Strong evidence (second-line) | Prevents biphasic reaction | 200 mg IV |
| Perioperative steroid cover (patient on chronic steroids) | Strong evidence | Replaces suppressed HPA axis | 50-100 mg IV |
| Adrenal insufficiency | Strong evidence | Hormone replacement | 50-200 mg IV |
Gentamicin used for??
| Category | Coverage |
|---|---|
| Gram-negative aerobes (primary use) | Pseudomonas aeruginosa, Klebsiella, E. coli, Proteus, Enterobacter, Serratia marcescens, Acinetobacter |
| Gram-positive (synergy only) | Staphylococcus aureus, Streptococcus, Enterococcus (only when combined with cell-wall agents) |
| No activity | Anaerobes (Bacteroides, Clostridium), Streptococci alone, most intracellular organisms |
| Organism | Combination |
|---|---|
| Enterococcal endocarditis | Gentamicin + Ampicillin OR Vancomycin |
| Streptococcal endocarditis | Gentamicin + Penicillin (shortens treatment duration) |
| Staphylococcal prosthetic valve endocarditis | Gentamicin + Vancomycin + Rifampicin |
Mechanism: Cell wall agents (penicillin, vancomycin) create pores in the gram-positive cell wall, allowing gentamicin to enter (normally excluded) → synergistic bactericidal killing. This synergy is the reason gentamicin is used even against organisms that seem "resistant" to it alone.
Important: For synergistic dosing in endocarditis, target peak 3-4 mcg/mL, much lower than standard dosing (peak 6-10 mcg/mL).
| Feature | Once-Daily (5-7 mg/kg/24h) | Divided (1.7-2 mg/kg q8h) |
|---|---|---|
| Pharmacology | Exploits concentration-dependent killing | Older method |
| Toxicity | Less nephrotoxic (long drug-free period allows renal recovery) | More cumulative renal exposure |
| Efficacy | Equal or better (higher peak/MIC ratio) | Standard |
| Preferred in | Most adult infections | Endocarditis, neonates, pregnancy |
| Parameter | Target |
|---|---|
| Peak (standard dosing) | 6-10 mcg/mL (general); 8-10 mcg/mL (severe sepsis, CF, osteomyelitis) |
| Trough | <2 mcg/mL (toxicity threshold) |
| Synergy dosing (endocarditis) | Peak 3-4 mcg/mL; Trough <1 mcg/mL |
| Sampling time | Trough: 30 min before 3rd dose; Peak: 30-60 min after 3rd dose |
| Situation | Action |
|---|---|
| Renal impairment | Reduce dose or extend interval; monitor TDM closely |
| Pre-existing hearing loss | Use with extreme caution or avoid |
| Concurrent loop diuretics | Avoid if possible; increases ototoxicity risk |
| Neuromuscular disease (myasthenia) | Avoid or use with extreme caution |
| Pregnancy | Avoid IV use (Category D); topical/ophthalmic = Category C |
| Anaerobic infections alone | Ineffective - add metronidazole |
| Monotherapy for pneumonia | Do not use alone - poor lung penetration |
| Feature | Details |
|---|---|
| Class | Aminoglycoside antibiotic |
| Source | Micromonospora purpurea |
| Action | Binds 30S ribosome → bactericidal |
| Spectrum | Gram-negative aerobes; synergy with gram-positives |
| No cover | Anaerobes, Streptococci (alone), intracellular organisms |
| Route | IV, IM, topical, ophthalmic, intratympanic, intrathecal |
| Main uses | Gram-negative sepsis, UTI, endocarditis (synergy), neonatal sepsis, eye infections |
| Dose (child) | 7.5 mg/kg/day ÷ q8h (normal renal function) |
| Monitor | Peak and trough levels; renal function; hearing |
| Key toxicities | Nephrotoxicity (reversible), Ototoxicity (irreversible), Neuromuscular blockade |